|
|
|
Provide life-enhancing products for kidney patients
About
Hancock Jaffe Laboratories’ mission is to develop and provide life-enhancing products and technologies which will improve quality of life for patients suffering from end stage renal disease (ESRD) and cardiovascular disease.
We commit to quality as the goal at every step of the process.
Hancock Jaffe Laboratories today
Since 2006, Hancock Jaffe Laboratories, Inc., based in Irvine, California, is a wholly-owned subsidiary of Leman Cardiovascular. Building upon a solid history of tissue technology, specifically glutaraldehyde fixation technology, and skilled manufacturing techniques, Hancock Jaffe Laboratories has successfully enhanced tissue preservation techniques and applied them to a unique range of bioprosthetic grafts.
All of the company's vascular grafts have received FDA clearance and are available for sale in the US. They are produced in a range of diameters and lengths for peripheral hemodialysis access. The company produces a series of high performance vascular tissue grafts which are used for redo vascular access in patients requiring hemodialysis.
Hancock Jaffe Laboratories was founded in 1987, by Warren Hancock and Norman Jaffe, with the goal of developing tissue-based solutions designed to help patients with end stage renal disease.
Both founders already possessed significant expertise, accumulated over many years, in the development of implantable biological prosthetic devices. Both the Hancock I and Hancock II porcine heart valves are implanted today in thousands of patients all over the world. Dr Jaffe developed the Intact valve. Both the Hancock valves and the Intact valve are marketed by Medtronic.
Milestones
|
